Dosage finding and outcome in the treatment of schizophrenic inpatients with amilsupride. Results of a drug utilization observation study

Human Psychopharmacology

Volumn 19, Issue 2, 2004, Pages 111-119

  Linden, Michael ^a,c   Scheel, Tabea ^a   Eich, Franz Xaver ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Division Henning   (Germany)

^c Rehabilitation Centre Seehof   (Germany)

Author keywords

Amisulpride; Antipsychotics; Dosage finding; Drug utilization; Epidemiology of care; Neuroleptic drugs; Quality assurance; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; TRANQUILIZER;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; DRUG UTILIZATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; HOSPITAL PATIENT; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; MENSTRUATION DISORDER; MULTIPLE REGRESSION; POLYPHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SKIN MANIFESTATION; SOCIAL PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; CHI-SQUARE DISTRIBUTION; DRUG UTILIZATION REVIEW; FEMALE; HOSPITALIZATION; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SULPIRIDE; TREATMENT OUTCOME;

EID: 1542620759     PISSN: 08856222     EISSN: None     Source Type: Journal    
DOI: 10.1002/hup.574     Document Type: Article

References (38)

1. Balestrieri M, Vampini C, Bellantuono C. 2000. Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol 15: 499-512.
2. Blin O. 2000. L'amisulpride: quelle place dans la réinsertion du patient schizophrène présentant des exacerbations aiguës. L'Encéphale 26(Spec 1): 7-11.
3. Boyer P, Lecrubier Y, Puech AJ, et al. 1995. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 166: 68-72.
4. Boyer P, Lecrubier Y, Rein W. 1994. Amisulpride, new data in the treatment of schizophrenia. Neuropsychopharmacology 10: 3S-804S.
5. Carpenter WT, Heinrichs DW, Wagman AMI. 1988. Deficit and non-deficit forms of schizophrenia: the concept. Am J Psychiatry 145: 578-583.
6. Carriere P, Bonhomme D, Lemperiere T. 2000. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study. The Amisulpride Study Group. Eur Psychiatry 15: 321-329.
7. Curran S, Harris L, Macdonald A, et al. 2002. Antipsychotics in clinical practice: guidelines for safe and effective use. Hum Psychopharmacol 17: 75-82.
8. Colonna L, Saleem P, Dondey-Nouvel L, et al. 2000. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol 15: 13-22.
9. Coulouvrat C, Dondey-Nouvel L. 1999. Safety of amisulpride (Solian): a review of 11 clinical studies. Int Clin Psychopharmacol 14: 209-218.
10. Danion JM, Rein W, Fleurot O. 1999. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 156: 610-616.
11. Farde L, Nordström AL, Karlsson P, et al. 1995. Positron emission tomography studies on dopamine receptors in schizophrenia. Clin Neuropharmacol 18(Suppl. 1): S121-S129.
12. Farde L, Nordström AL, Wiesel FA, et al. 1992. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side-effects. Arch Gen Psychiatry 49: 538-544.
13. Freeman HL. 1997. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol 12(Suppl. 2): S11-S17.
14. Hillert A, Philipp M, Gattaz WF, et al. 1994. Amisulpride versus flupenthixol in the treatment of schizophrenia with predominant positive symptomatology: a controlled double-blind study [abstract]. Neuropharmacology 10(Suppl. 3, part 2): S31.
15. Lecrubier Y. 2000. Is amisulpride an 'atypical' atypical antipsychotic agent? Int Clin Psychopharmacol 15(Suppl. 4): S21-S26.
16. Lecrubier Y, Azorin M, Bottai T, et al. 2001. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 44: 41-46.
17. Legangneux E, Mc Ewen J, Wesnes KA, et al. 2000. The acute effects of amisulpride (50mg and 200mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. J Psychopharmacol 14: 164-171.
18. Leucht S, Pitschel-Walz G, Engel RR, et al. 2002. Amisulpride, an unusual 'atypical' antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 159: 180-190.
19. Linden M. 1989. Die Phase IV der Therapie-Evaluation. Nervenarzt 60: 453-461.
20. Linden M. 1992. Epidemiological methods in the evaluation of drugs. Field studies in the post-marketing phase. Pharmacopsychiatry 25: 67-68.
21. Linden M. 1994. Therapeutic standards in psychopharmacology and medical decision-making. Pharmacopsychiatry 27(Suppl.): 41-45.
22. Linden M. 1997. Phase IV research and drug utilization observation studies. Pharmacopsychiatry 30: 1-3.
23. Loo H, Poirier-Littre MF, Théron M, et al. 1997. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 170: 18-22.
24. Martin S, Ljo H, Peuskens J, et al. 2002. A double-blind, randomized comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr Med Res Opin 18: 355-362.
25. Martinot JL, Paillère-Martinot ML, Poirier MF, et al. 1996. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124: 154-158.
26. Mauri MC, Bravin S, Bitetto A, et al. 1996. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf 14: 288-298.
27. Möller HJ, Boyer P, Fleurot O, et al. 1997. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison to haloperidol. Psychopharmacology 132: 396-401.
28. Paillère-Martinot M-L, Lecrubier Y, Martinot J-L, et al. 1995. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry 152: 130-133.
29. Peuskens J, Bech P, Moller HJ, et al. 1999. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride Study Group. Psychiatry Res 88: 107-117.
30. Puech A, Fleurot O, Rein W. 1998. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 98: 65-72.
31. Puech A, Fleurot O, Rein W, et al. 1996. Amisulpride in the treatment of acute exacerbations of subchronic or chronic schizophrenia: a dose-range finding study [abstract]. Eur Psychiatry 11(Suppl. 4): 280S.
32. Rein W, Turjanski S. 1997. Clinical update on amisulpride in deficit schizophrenia. Int Clin Psychopharmacol 12(Suppl. 2): S19-S27.
33. Rosenzweig P, Canal M, Patat A, et al. 2002. A review of the Pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 17: 1-13.
34. Schlösser R, Gründer G, Anghelescu I, et al. 2002. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 46: 33-40.
35. Sechter D, Peuskens J, Fleurot O, et al. 2002. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 27: 1071-1081.
36. Soares BGO, Fenton M, Chue P. 2001. Sulpiride for schizophrenia (Cochrane Review). In The Cochrane Library, Issue 3. Update Software: Oxford.
37. van Putten T, May PR. 1978. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiat 35: 477-480.
38. Wetzel H, Grunder G, Hillert A, et al. 1998. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology 137: 223-232.